506 related articles for article (PubMed ID: 33434185)
1. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis.
Mohapatra P; Shriwas O; Mohanty S; Ghosh A; Smita S; Kaushik SR; Arya R; Rath R; Das Majumdar SK; Muduly DK; Raghav SK; Nanda RK; Dash R
JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434185
[TBL] [Abstract][Full Text] [Related]
2. CMTM6 attenuates cisplatin-induced cell death in OSCC by regulating AKT/c-Myc-driven ribosome biogenesis.
Mohapatra P; Mohanty S; Ansari SA; Shriwas O; Ghosh A; Rath R; Majumdar SKD; Swain RK; Raghav SK; Dash R
FASEB J; 2022 Oct; 36(10):e22566. PubMed ID: 36165231
[TBL] [Abstract][Full Text] [Related]
3. STAT3- and GSK3β-mediated Mcl-1 regulation modulates TPF resistance in oral squamous cell carcinoma.
Maji S; Shriwas O; Samal SK; Priyadarshini M; Rath R; Panda S; Das Majumdar SK; Muduly DK; Dash R
Carcinogenesis; 2019 Mar; 40(1):173-183. PubMed ID: 30395230
[TBL] [Abstract][Full Text] [Related]
4. OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway.
Pang X; Wang SS; Zhang M; Jiang J; Fan HY; Wu JS; Wang HF; Liang XH; Tang YL
Cancer Immunol Immunother; 2021 Apr; 70(4):1015-1029. PubMed ID: 33104837
[TBL] [Abstract][Full Text] [Related]
5. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
[TBL] [Abstract][Full Text] [Related]
6. Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3β signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants (v4 and v6) in oral cancer.
Kashyap T; Pramanik KK; Nath N; Mishra P; Singh AK; Nagini S; Rana A; Mishra R
Oral Oncol; 2018 Nov; 86():234-243. PubMed ID: 30409306
[TBL] [Abstract][Full Text] [Related]
7. SOX8 regulates cancer stem-like properties and cisplatin-induced EMT in tongue squamous cell carcinoma by acting on the Wnt/β-catenin pathway.
Xie SL; Fan S; Zhang SY; Chen WX; Li QX; Pan GK; Zhang HQ; Wang WW; Weng B; Zhang Z; Li JS; Lin ZY
Int J Cancer; 2018 Mar; 142(6):1252-1265. PubMed ID: 29071717
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of lncRNA FTH1P3 promotes oral squamous cell carcinoma cells migration and invasion by enhancing PI3K/Akt/GSK3b/ Wnt/β-catenin signaling.
Liu M; Gao X; Liu CL
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8306-8314. PubMed ID: 30556871
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma.
Shen B; Huang D; Ramsey AJ; Ig-Izevbekhai K; Zhang K; Lajud SA; O'Malley BW; Li D
Br J Cancer; 2020 Mar; 122(5):640-647. PubMed ID: 31853007
[TBL] [Abstract][Full Text] [Related]
10. WNT3 promotes chemoresistance to 5-Fluorouracil in oral squamous cell carcinoma via activating the canonical β-catenin pathway.
Zhang X; Sun K; Gan R; Yan Y; Zhang C; Zheng D; Lu Y
BMC Cancer; 2024 May; 24(1):564. PubMed ID: 38711026
[TBL] [Abstract][Full Text] [Related]
11. Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma.
Liu T; Chen G; Sun D; Lei M; Li Y; Zhou C; Li X; Xue W; Wang H; Liu C; Xu J
Acta Biochim Biophys Sin (Shanghai); 2017 Sep; 49(9):808-816. PubMed ID: 28910982
[TBL] [Abstract][Full Text] [Related]
12. LncRNA HOXA11-AS Promotes Proliferation and Cisplatin Resistance of Oral Squamous Cell Carcinoma by Suppression of miR-214-3p Expression.
Wang X; Li H; Shi J
Biomed Res Int; 2019; 2019():8645153. PubMed ID: 31275988
[TBL] [Abstract][Full Text] [Related]
13. Up-regulation of TNF-alpha/NFkB/SIRT1 axis drives aggressiveness and cancer stem cells accumulation in chemoresistant oral squamous cell carcinoma.
de Castro LR; de Oliveira LD; Milan TM; Eskenazi APE; Bighetti-Trevisan RL; de Almeida OGG; Amorim MLM; Squarize CH; Castilho RM; de Almeida LO
J Cell Physiol; 2024 Feb; 239(2):e31164. PubMed ID: 38149816
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-485-5p targets keratin 17 to regulate oral cancer stemness and chemoresistance via the integrin/FAK/Src/ERK/β-catenin pathway.
Jang TH; Huang WC; Tung SL; Lin SC; Chen PM; Cho CY; Yang YY; Yen TC; Lo GH; Chuang SE; Wang LH
J Biomed Sci; 2022 Jun; 29(1):42. PubMed ID: 35706019
[TBL] [Abstract][Full Text] [Related]
15. RRBP1 rewires cisplatin resistance in oral squamous cell carcinoma by regulating Hippo pathway.
Shriwas O; Arya R; Mohanty S; Mohapatra P; Kumar S; Rath R; Kaushik SR; Pahwa F; Murmu KC; Majumdar SKD; Muduly DK; Dixit A; Prasad P; Nanda RK; Dash R
Br J Cancer; 2021 Jun; 124(12):2004-2016. PubMed ID: 33762722
[TBL] [Abstract][Full Text] [Related]
16. CerS6 regulates cisplatin resistance in oral squamous cell carcinoma by altering mitochondrial fission and autophagy.
Li S; Wu Y; Ding Y; Yu M; Ai Z
J Cell Physiol; 2018 Dec; 233(12):9416-9425. PubMed ID: 30054909
[TBL] [Abstract][Full Text] [Related]
17. Autophagy-related CMTM6 promotes glioblastoma progression by activating Wnt/β-catenin pathway and acts as an onco-immunological biomarker.
Dai L; Xiao J; Li X; Tao Y; Zhou P; Lyu L; Shi Z; Liang X; Jia Z; Jiang S
J Gene Med; 2024 May; 26(5):e3685. PubMed ID: 38686653
[TBL] [Abstract][Full Text] [Related]
18. Bcl-xL expression and regulation in the progression, recurrence, and cisplatin resistance of oral cancer.
Alam M; Mishra R
Life Sci; 2021 Sep; 280():119705. PubMed ID: 34111459
[TBL] [Abstract][Full Text] [Related]
19. CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma.
Zhang S; Yan Q; Wei S; Feng X; Xue M; Liu L; Cui J; Zhang Y
Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Aug; 132(2):202-209. PubMed ID: 34034998
[TBL] [Abstract][Full Text] [Related]
20. Interplay between EZH2/β-catenin in stemness of cisplatin-resistant HNSCC and their role as therapeutic targets.
Milan TM; Eskenazi APE; Oliveira LD; Silva GD; Bighetti-Trevisan RL; Freitas GP; Almeida LO
Cell Signal; 2023 Sep; 109():110773. PubMed ID: 37331417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]